King Gaston N, Cochran David L
Department of Periodontology, St Bartholomew's & the Royal London School of Medicine & Dentistry, Queen Mary College, University of London, UK.
J Periodontol. 2002 Aug;73(8):925-36. doi: 10.1902/jop.2002.73.8.925.
The healing process initiated by a single molecular species of bone morphogenetic protein (BMP) such as BMP-2 or BMP-7 sets in motion a cascade of cellular events resulting in differentiation of progenitor cells into phenotypes involved in periodontal regeneration. For example, animal studies show that a single dose of recombinant human (rh) BMP-2 increases the rate of normal intramembranous bone formation and enhanced cementum formation during periodontal wound healing. However, the optimal effects of BMPs are modulated by a range of factors that need careful evaluation in clinical studies. These factors include the influence of root conditioning, occlusal loading, BMP dose, and the release characteristics of the carrier as well as the suitability of the model to evaluate the efficacy of BMPs. Each of these factors may affect the rate of BMP-induced osteogenesis and cementogenesis and subsequent periodontal ligament (PDL) formation during the early and late stages of periodontal wound healing. Although BMP-2 initiates stem cells along an osteogenic pathway, the dose may have to be of sufficient concentration to ensure other growth and differentiation factors do not redirect or retard the osteogenic potential of the cell. Understanding when to manipulate the cell's differentiation pathway with the application of single or multiple doses of BMPs at the appropriate concentration is required to optimize the effect of BMPs in periodontal wound healing. Therefore, different release profiles from the same carrier may be particularly important in tissues with mixed cell populations such as in the periodontium, where similar tissues like bone and cementum grow at different rates. Furthermore, treatment of intrabony defects with BMPs are likely to not only require appropriate temporal release of the BMP(s), but also a carrier that can serve as a template for new tissue formation providing space maintenance and supporting the mucoperiosteal flap. Many of these issues have not been adequately addressed from a periodontal standpoint; therefore the purpose of this review is to clarify our current understanding of the factors that are likely to modulate the effects of BMP-induced periodontal regeneration. Moreover, assessing the importance of these factors is essential prior to conducting expensive human clinical trials.
由单一分子种类的骨形态发生蛋白(BMP)(如BMP-2或BMP-7)启动的愈合过程引发了一系列细胞事件,导致祖细胞分化为参与牙周再生的表型。例如,动物研究表明,单剂量的重组人(rh)BMP-2可提高正常膜内骨形成的速率,并在牙周伤口愈合过程中增强牙骨质形成。然而,BMP的最佳效果受到一系列因素的调节,这些因素需要在临床研究中仔细评估。这些因素包括牙根预处理、咬合负荷、BMP剂量、载体的释放特性以及评估BMP疗效的模型的适用性。这些因素中的每一个都可能影响BMP诱导的成骨和牙骨质生成速率以及牙周伤口愈合早期和晚期随后的牙周韧带(PDL)形成。虽然BMP-2沿着成骨途径启动干细胞,但剂量可能必须足够高,以确保其他生长和分化因子不会改变或阻碍细胞的成骨潜力。为了优化BMP在牙周伤口愈合中的效果,需要了解何时以适当的浓度应用单剂量或多剂量的BMP来操纵细胞的分化途径。因此,同一载体的不同释放曲线在具有混合细胞群体的组织(如牙周组织)中可能尤为重要,在牙周组织中,骨和牙骨质等相似组织以不同的速率生长。此外,用BMP治疗骨内缺损可能不仅需要BMP的适当时间释放,还需要一种载体,该载体可以作为新组织形成的模板,提供空间维持并支撑粘骨膜瓣。从牙周角度来看,许多这些问题尚未得到充分解决;因此,本综述的目的是阐明我们目前对可能调节BMP诱导的牙周再生效果的因素的理解。此外,在进行昂贵的人体临床试验之前,评估这些因素的重要性至关重要。